Serum lipids might improve prostate-specific antigen sensitivity in patients undergoing transrectal ultrasonography-guided biopsy for suspected prostate cancer: A pilot study

• Published in: Arab Journal of Urology 2019-07, Vol.17 (3), p.195-199
• Main Authors: Harraz, Ahmed M., Atia, Nora, Ismail, Amani, Abol-Enein, Hassan, Abdel-Aziz, A.F.
• Format: Article
• Language: English
• Subjects: LDL; metabolic syndrome; Oncology/Reconstruction; Prostate cancer; PSA; serum lipids; TRUS-guided biopsy
• ISSN: 2090-598X; 2090-598X; 2090-5998
• DOI: 10.1080/2090598X.2019.1626126

Objectives: To investigate the potential use of body mass index (BMI) and serum lipids in improving prostate-specific antigen (PSA) sensitivity in patients undergoing biopsy for suspicion of prostate cancer, as there is an established relationship between metabolic syndrome, obesity and serum lipids with prostate cancer. Patients and methods: A pilot study was conducted in a tertiary referral centre between June 2016 and August 2017 of patients undergoing transrectal ultrasonography (TRUS)-guided biopsy. After the result of TRUS-biopsy, the first 50 patients diagnosed with prostate cancer (study group) and those with no prostate cancer (control group) were enrolled. BMI, serum PSA level, fasting blood sugar and lipid profile (e.g. cholesterol, triglycerides, low-density lipoprotein [LDL] and high-density lipoprotein [HDL]), were compared between the groups. Results: Higher BMI, cholesterol, LDL and lower HDL together with PSA were significantly associated with a positive biopsy. On multivariate analysis, LDL (odds ratio [OR] 5.3, 95% confidence interval [CI] 1.2-24.9; P = 0.03) and total PSA level (OR 12.9, 95% CI 4.7-35; P